Please use this identifier to cite or link to this item:
|Title:||Drug repurposing of minocycline against dengue virus infection|
|Authors:||Shilpa Lekshmi Leela|
Gopinathan Pillai Sreekanth
Pa thai Yenchitsomanus
Thailand National Science and Technology Development Agency
|Keywords:||Biochemistry, Genetics and Molecular Biology|
|Citation:||Biochemical and Biophysical Research Communications. Vol.478, No.1 (2016), 410-416|
|Abstract:||© 2016 Elsevier Inc. Dengue virus infection is one of the most common arthropod-borne viral diseases. A complex interplay between host and viral factors contributes to the severity of infection. The antiviral effects of three antibiotics, lomefloxacin, netilmicin, and minocycline, were examined in this study, and minocycline was found to be a promising drug. This antiviral effect was confirmed in all four serotypes of the virus. The effects of minocycline at various stages of the viral life cycle, such as during viral RNA synthesis, intracellular envelope protein expression, and the production of infectious virions, were examined and found to be significantly reduced by minocycline treatment. Minocycline also modulated host factors, including the phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2). The transcription of antiviral genes, including 2′-5′-oligoadenylate synthetase 1 (OAS1), 2′-5′-oligoadenylate synthetase 3 (OAS3), and interferon α (IFNA), was upregulated by minocycline treatment. Therefore, the antiviral activity of minocycline may have a potential clinical use against Dengue virus infection.|
|Appears in Collections:||Scopus 2016-2017|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.